Open Question

Can a scanner-transferable, prospectively-validated imaging rule distinguish true early progression from treatment effect (pseudoprogression) at the individual-patient level?

Evidence grade: UNRESOLVED-CONTROVERSY — Genuinely unsettled — the evidence conflicts.

Why it matters

This is the single most common unresolved daily decision in neuro-oncology; current practice defaults to watchful waiting, delaying effective therapy or prolonging toxic ineffective therapy.

Conflicting evidence

Cohort-level separation exists (perfusion, PET) but thresholds do not transfer across sites; RANO 2.0 still relies on confirmation scans.

What would resolve it

Prospective multi-vendor cohort with biopsy/long-follow-up ground truth, pre-registered thresholds, calibration + decision-curve analysis; amino-acid PET arm where available.

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.